ArticleInternational ophthalmology2025
Intravitreal injection of SARM1 siRNA in TNF-induced optic nerve degeneration.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeIntravitreal injections of some drugs such as anti-VEGF antibodies are available for certain human ocular diseases. Meanwhile, inhibition of SARM1 has been reported to exert neuroprotection in several neurodegenerative disease models. The aim of the current study is to investigate whether intravitreal injection of SARM1 siRNA can protect axons against TNF-induced optic nerve degeneration model.
methodsRats were received with intravitreal injection of PBS, TNF, TNF + SARM1 siRNA or SARM1 siRNA alone. Pre-injection of SARM1 siRNA + TNF and pre-injection of control siRNA + TNF groups were also made. Immunoblot analysis was carried out to evaluate SARM1 expression in the optic nerve. Morphometric analysis was carried out to evaluate the effects of SARM1 siRNA against axon loss induced by TNF. Immunohistochemical analysis was carried out to examine the localization of SARM1 in cross-sectioned optic nerves.
resultsImmunoblot analysis showed that intravitreal injection of SARM1 siRNA significantly decreased the SARM1 protein level in the optic nerve. Unexpectedly, axonal loss in the simultaneous intravitreal injection of SARM1 and TNF was almost the same as that in the TNF injection alone group. Pre-injection of SARM1 siRNA did not prevent axonal loss induced by TNF. There were no changes in SARM1 protein level in optic nerves 1 week after TNF injection compared with the PBS-injected group. Immunohistochemical analysis showed that the SARM1 immunoreactivity was colocalized with GFAP immunoreactivity in cross-sectioned optic nerves in both TNF and control groups.
conclusionThese results suggest that intravitreal injection of SARM1 siRNA may not prevent axonal degeneration induced by TNF.
Indexed as
Identifiers
41117976What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.